ResMed Balance Sheet Health
Financial Health criteria checks 6/6
ResMed has a total shareholder equity of $4.6B and total debt of $1.0B, which brings its debt-to-equity ratio to 21.7%. Its total assets and total liabilities are $6.8B and $2.2B respectively. ResMed's EBIT is $1.3B making its interest coverage ratio 23.6. It has cash and short-term investments of $259.4M.
Key information
21.7%
Debt to equity ratio
US$1.01b
Debt
| Interest coverage ratio | 23.6x |
| Cash | US$259.45m |
| Equity | US$4.63b |
| Total liabilities | US$2.18b |
| Total assets | US$6.81b |
Recent financial health updates
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06Recent updates
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06ResMed: The GARP Story Continues, Technicals Showing Vital Signs
Jan 26Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention
Jan 23We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease
Dec 28Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)
Dec 16ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends
Nov 14Financial Position Analysis
Short Term Liabilities: RMD's short term assets ($2.4B) exceed its short term liabilities ($773.0M).
Long Term Liabilities: RMD's short term assets ($2.4B) exceed its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: RMD's net debt to equity ratio (16.1%) is considered satisfactory.
Reducing Debt: RMD's debt to equity ratio has reduced from 66.1% to 21.7% over the past 5 years.
Debt Coverage: RMD's debt is well covered by operating cash flow (119%).
Interest Coverage: RMD's interest payments on its debt are well covered by EBIT (23.6x coverage).